All Around Space Agency
Expedition overview
Time is the greatest obstacle in medical research. At All Around Space, we act as your dedicated Agent and Assistant, streamlining the connection between Earth-based laboratories and the unique research environment of microgravity. Our goal is to handle the logistical coordination and advocate for your mission, ensuring it is expedited so you can focus on the science that benefits all humankind.
All Around Space Agency is an early-stage venture. The service model described on this page is our intended structure, not a description of services currently in operation. We hold no partnership, agency, or representation agreement with any launch provider, station operator, or company named on this site. Named organisations are referenced for market context only.
We don’t build the hardware; we provide the Bridge.
As a platform-agnostic agency, we serve as a Market Maker — matching your scientific goals with the most cost-effective and efficient flight-certified providers in the industry.
We identify your research objectives and the specific physical bottlenecks you are facing in your current Earth-based lab.
We would survey available capacity across flight providers to identify a suitable orbital platform, timeline, and price for your payload.
We support you through the entire process as your assistant, helping you navigate the pathway to orbit so you can focus on the experiment, not the logistics.
Once your orbital data is gathered, we assist in the transition of that information to FindTheCure.AI, where deep-learning analysis is intended to help break down the findings to identify potential medical breakthroughs.
Intended structure: a comprehensive roadmap for your research, evaluating hardware compatibility and flight availability to provide a “Go / No-Go” plan.
Intended structure: acting as your dedicated agent from booking to splashdown, handling rideshare logistics to expedite your launch.
Intended structure: ongoing “Space Desk” monitoring of new launch opportunities and emerging technologies to keep your lab at the forefront.
Four applications where orbit does something Earth physically cannot.
The science: In microgravity, liver cells self-assemble into functional 3D liver organoids. These “mini-livers” develop blood-vessel mimics and metabolize drugs more accurately than flat Earth-based samples.
Support: UCSF Research — How Liver Tissue from the ISS May Transform Tissue Engineering
Status: Research presented at the American College of Surgeons (2024).
The science: Cancer cells in orbit naturally form 3D multicellular spheres. These models mirror the structure of real tumors, allowing for higher-accuracy drug testing than 2D Earth samples.
Support: Stem Cells Translational Medicine (2025) — effects of microgravity on cancer cells.
The science: Space acts as a “fast-forward” environment for bone loss — roughly 10× faster than Earth. This allows rapid testing of treatments for osteoporosis and muscle wasting.
Support: NASA Spinoff — Rodent Research Contributes to Osteoporosis Treatments (Amgen / Denosumab).
The science: Without gravity, protein crystals grow more uniform, providing superior data for drug formulation.
Support: ISS National Lab — Merck Lab publishes Keytruda results.
Result: Led to a one-minute injectable version of the cancer drug.
AllAroundSpace.agency is the commercial engine that fuels our primary mission. By assisting researchers in reaching orbit faster and gathering higher-fidelity data, the intent is to generate the resources and information necessary to drive our deep-learning initiative at FindTheCure.AI.
Development stage. All Around Space Agency is an early-stage venture. Services described are an intended model and are not currently in operation. We have no partnership, agency, representation, or supplier agreement with any launch provider, station operator, research organisation, or company named or referenced on this site.
The Agency is designed to act solely as a logistics broker, agent, and coordinator. We do not operate launch vehicles, orbital platforms, or laboratory hardware, and we do not conduct research ourselves.
Case studies referenced on this page describe published third-party research and are provided for illustration. They do not represent results produced by the Agency, nor a guarantee of results for any client mission.
Space launch is inherently risky. In the event of launch vehicle failure, deployment failure, or loss of payload, the Agency is not liable for the value of scientific payloads, research data, or development costs. Clients are responsible for procuring their own launch insurance if desired.
Manifest availability and flight approval remain at the sole discretion of launch providers and governing regulatory bodies. Nothing on this page constitutes medical, legal, or investment advice.
The International Space Station is scheduled for retirement in 2030, and NASA is transitioning from station operator to customer — buying research services from commercial platforms rather than running its own. Orbital research capacity is being rebuilt from scratch, and early allocations are being claimed now. Verified: Sep 2026
Commercial stations are coming online with meaningfully smaller research capacity than the ISS provided. Vast’s Haven-1, targeted to launch in 2027, supports roughly 160 astronaut-days of research, manufacturing, and technology testing across its service life, and its payload partners already include Redwire, Yuri Gravity, JAMSS, Interstellar Lab, and Exobiosphere. Axiom Station’s first module (AxPPTM) is targeted for late 2027, with a free-flying two-module station expected in 2028. Verified: Sep 2026 Verified: Sep 2026
A shrinking number of slots, a hard 2030 deadline, and a fragmented provider landscape. That is exactly when an agent matters.
Varda announced a collaboration with United Therapeutics to study microgravity in developing improved formulations for rare pulmonary disease — reported as among the first instances of a publicly traded pharmaceutical company committing its own capital to commercial space-based drug manufacturing rather than relying on government-funded research.
Reported: MIT Technology Review, May 2026.
Prior flight heritage: Varda grew ritonavir crystals on its first orbital capsule mission, with further capsules flown since.
Microgravity crystallisation has moved from academic curiosity to a line item in pharmaceutical R&D budgets. The question facing research institutions is no longer whether orbit produces better data — it is who can get them there, and how quickly.
Our role: we do not manufacture in orbit. We broker the access, compress the timeline, and route the returned data into deep-learning analysis.
Tell us your research objective and the bottleneck you’re hitting on Earth. We’ll tell you whether microgravity solves it — and what it takes to fly.
Start a feasibility study →